BioAge Labs, Inc.
BIOA$113M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaEMERYVILLE
Drugs in Pipeline
6
Phase 3 Programs
4
Upcoming Catalysts
2
Next Catalyst
Aug 5, 2026
6wMarket Overview
Stock performance and key metrics
BIOA News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
FG-4592
Anemia
N1539
Pain, Postoperative
JOINTSTEM
Degenerative Arthritis
Roxadustat
Chemotherapy Induced Anemia
Oral BGE-102
Obesity and Cardiovascular Risk
Brequinar
COVID-19
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FG-4592 | Phase 3 | Anemia | - | - |
N1539 | Phase 3 | Pain, Postoperative | - | - |
JOINTSTEM | Phase 3 | Degenerative Arthritis | - | - |
Roxadustat | Phase 3 | Chemotherapy Induced Anemia | - | - |
Oral BGE-102 | Phase 2 | Obesity and Cardiovascular Risk | - | - |
Brequinar | Phase 2 | COVID-19 | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply